Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion

Netherlands Heart Journal

Volumn 24, Issue 10, 2016, Pages 609-616

  Yuksel, I O ^a   Cagirci, G ^a   Koklu, E ^a   Yilmaz, A ^a   Kucukseymen, S ^a   Ellidag, H Y ^a   Cay, S ^b   Yilmaz, N ^a   Arslan, S ^a  

^a Antalya Education and Research Hospital ^*  (Turkey)

^b Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

Author keywords

Chronic total occlusions; Coronary collateral development; Serum erythropoietin level

Indexed keywords

ERYTHROPOIETIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OCCLUSION; CORONARY COLLATERAL DEVELOPMENT; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY);

EID: 84992107946     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-016-0875-x     Document Type: Article

References (26)

1. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation. 1986;11:469–76.
2. IJkema BB, Bonnier JJ, Schoors D, Schalij MJ, Swenne CA. Role of the ECG in initial acute coronary syndrome triage: primary PCI regardless presence of ST elevation or of non-ST elevation. Neth Heart J. 2014;22(11):484–90. doi:10.1007/s12471-014-0598-9.
3. Sellke FW, Wang SY, Stamler A, et al. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol. 1996;271:713–20.
4. Sato T, Maekawa T, Watanabe S, Tsuji K, Nakahata T. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest. 2000;106:263–70.
5. Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018–27.
6. Hakimzadeh N, Piek JJ. The coronary collateral circulation revisited. Neth Heart J. 2013;21:144–5
7. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;1:3.
8. Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009;30:253–60.
9. de Seigneux S, Ponte B, Weiss L, et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol. 2012;13:132.
10. Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J. 2012;33(5):614–21.
11. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973–9.
12. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45(9):1406–12.
13. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct sizein the myocardium in vitro. Cardiovasc Drugs Ther. 2005;19:333–6.
14. Marrero MB, Venema RC, Ma H, Ling BN, Eaton DC. Erythropoietin receptor-operated Ca2 channels: activation by phospholipase C-gamma 1. Kidney Int. 1998;53:1259–68.
15. Akimoto T, Kusano E, Inaba T, et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int. 2000;58:269–82.
16. Ammarguellat F, Llovera M, Kelly PA, Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2001;284:1031–8.
17. Akimoto T, Kusano E, Ito C, et al. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens. 2001;19:193–202.
18. Gogusev J, Zhu DL, Hérembert T, Ammarguellat F, Marche P, Drueke T. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1994;199:977–83.
19. Silverberg DS, Wexler D, Sheps D, et al. The effect of correctionof mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.
20. Guo L, Wang A, Sun Y, Lv L, Xu CE. Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia. Exp Ther Med. 2013;6:1327–31.
21. Ziabakhsh-Tabary S, Jalalian R, Mokhtari-Esbuie F, Habibi MR. Echocardiographic evaluation of the effects of a single bolus of rrythropoietin on reducing ischemia-reperfusion injuries during coronary artery bypass graft surgery; a randomized, double-blind, placebo-control study. Iran J Med Sci. 2014;39:94–101.
22. Sahinarslan A, Yalcin R, Kocaman SA, et al. The relationship of serum erythropoietin level with coronary collateral grade. Can J Cardiol. 2011;27:589–95.
23. Xu W, Guo Z, Mi L, Wang G. Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion. Biomarkers. 2013;18:343–8.
24. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol. 2003;23:1143–51.
25. Zafiriou MP, Noack C, Unsöld B, et al. Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction. Neth Heart J. 2013;21(3):144–5.
26. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care. 2013;17:254.